Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Edward Mitchell
Medical College of Wisconsin, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ariosa Diagnostics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This research aims to develop a noninvasive biomarker for transplant rejection. Ariosa Diagnostics, Inc (Ariosa) is a molecular diagnostics company that has licensed IP invented by Michael Mitchell and Aoy Tomita-Mitchell, and developed and commercialized a clinical test for detecting fetal chromosomal abnormalities from maternal blood. The same assay can be used to quantify donor DNA present in recipient plasma in research but requires additional data from our lab at MCW. In this study, the Mitchells will utilize the assay developed by Ariosa off label because it is the fastest way to achieve accurate data in order to advance an in-house test optimized for transplant rejection monitoring. The Mitchells have no current role in the management of Ariosa. Any new inventions of the Mitchells under this federally funded grant will be owned by and licensing will be controlled by the Medical College of Wisconsin.
Targeted, Highly Sensitive, Non-Invasive Cardiac Transplant Rejection Monitoring
We will develop a non-invasive method for monitoring rejection in children and adults with heart transplants. The current gold standard for rejection monitoring is done by biopsy, which is costly and accompanied by risk, especially for children. Our method is rapid, safe and cost effective enabling sensitive high frequency monitoring with short and long term benefits for all transplant recipients.
Filed on September 12, 2013.
Tell us what you know about Michael Edward Mitchell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Michael Edward Mitchell filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Mitchell | Medical College of Wisconsin | Conflict of Interest | TAI Diagnostics, LLC | Value cannot be readily determined |
| Michael Edward Mitchell | Medical College of Wisconsin | Conflict of Interest | Ariosa Diagnostics, Inc. | Value cannot be readily determined |
| Michael Mitchell | Medical College of Wisconsin | Conflict of Interest | TAI Diagnostics, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.